In rheumatoid arthritis patients, clinical response to abatacept, a CD80/86-CD28 T cell co-stimulation modulator, is associated with a concomitant decrease in CD8+CD28− T cells, suggesting prognostic value for this phenotype [56]. The gene discussed is CD8A; the disease is rheumatoid arthritis.